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a  b  s  t  r  a  c  t
Early  management  in oncology  is based  on  coordination  and  high-quality  exchange  between  the  vari-
ous  health-care  partners.  The  present  guidelines  are  based  on a  literature  search  with  levels  of  evidence.
Treatment  waiting  time  can  be optimized  by performing  assessment  as  early  as  possible  (Expert  opinion),
to  limit the  interval  (ideally,  less  than  4 weeks)  between  ﬁrst consultation  and  data  collection.  In the  ﬁrst
specialist  consultation,  diagnostic  work-up  should  be scheduled  and  the  data  required  for  management
should  be determined  (Grade  B).  Work-up  may  be  conducted  on  a  day-care  basis  or with  conventional
admission  (Expert  opinion).  The  patient’s  medico-social  context  should  be taken  into  account  from  the
outset,  with  social  work  involvement  whenever  necessary  (Expert  opinion).  Pain  and  nutritional  manage-
ment  should  be  planned  for  (Grade  A)  and  realistic  therapeutic  education  be provided  (Expert  opinion).
Community-hospital  teamwork  for supportive  care  should  be optimized  (Expert  opinion).  Management
should  be early  and  multidisciplinary,  to shorten  delay  between  diagnosis  and  treatment  initiation.Abbreviations: INCa, French National Cancer Institute (Institut National du Can-
er);  ENT, Ear, Nose and Throat; MDTM,  Multidisciplinary team meeting; BMI, Body
ass index; WHO, World Health Organization; SFORL, French Society of ENT (Société
ranc¸ aise d’Oto-Rhino-Laryngologie).
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1. Introduction
Objective No. 2 of the French 2014–2019 Cancer Plan III [1] aims
to optimize quality and safety in the management of cancerous
disease (Expert opinion). This is to be achieved by improving the
continuum between the various steps of the care pathway: i.e.,
improved coordination and exchange of high-quality information
between the various health-care professionals involved.
Several points need working on to optimize early manage-
ment of head and neck tumor: notably, treatment waiting time,
206 F. Cuny et al. / European Annals of Otorhinolaryngolog
Table 1
Correspondence between literature assessment and guidelines grading (adapted
Sackett score).
Level of evidence according to literature Strength of
recommendation
Text Position paper Guideline
Level 1
High-power randomized comparative trial
Meta-analysis of randomized comparative trials
Decision analysis founded on well-conducted
studies
Grade A
High level of evidence
Level 2










Comparative study with signiﬁcant bias
Retrospective study
Case series
Descriptive epidemiological study (transversal,
longitudinal)
Grade C
Low level of evidence




Adapted from the French National Health Accreditation and Assessment Agency guide
(ANAES) literature assessment and guidelines grading guide (January 2000).
The present classiﬁcation is intended to clarify the bases on which guidelines are
drawn up. Absence of level of evidence should encourage further studies when pos-

























[uideline is not relevant or useful (e.g., efﬁcacy of mastectomy in breast cancer, of
ntibiotics in pharyngitis, etc).
a Unless otherwise stated, guidelines are based on expert opinion.
rganization of the ﬁrst consultation, and rapid initiation of sup-
ortive care so as not to delay treatment.
The present paper does not cover guidelines for the consulta-
ion communicating the diagnosis, multidisciplinary team meeting
MDTM), communication of the personalized treatment plan or
etting up the therapy project.
. Methodology
Guidelines were graded A, B or C according to decreasing level of
vidence, in line with the guide to literature analysis and guidelines
rading published by the French National Agency for Accreditation
nd Evaluation in Health (ANAES) (January 2000) (Table 1).
. The issue of delays
The literature describes two relevant delays: “patient”, and
professional” [2] (level of evidence 4). The patient delay is the
nterval between symptom onset and ﬁrst medical consultation;
rofessional delay begins when the patient ﬁrst sees a physician
specialist or general practitioner); but this varies between publica-
ions, some putting the starting point when the patient is admitted
o a specialized center and terminating with the initiation of treat-
ent [2] (level of evidence 4). Management delay may  occur at all
tages, especially before the ﬁrst consultation, and is a major issue
n head and neck oncology.
.1. Patient delay and referral timeA meta-analysis of 18 studies of oral cavity cancer showed the
atient delay to be the main factor of delay, with intervals ranging
rom 3.5 to 5.4 months. The professional delay comes on top of this
2] (level of evidence 4). Referral time (between when the patient isy, Head and Neck diseases 132 (2015) 205–208
seen by a health-care professional who  suspects cancer and when
the patient is referred to an oncology specialist) can be shortened
at several levels [1] (Expert opinion) by:
• improved awareness in community physicians and dental sur-
geons (or other health-care professionals) regarding head and
neck cancer screening;
• information on centers managing head and neck cancer;
• facilitating the procedure (telephone, secretariat) for appoint-
ments with appropriate specialists.
3.2. Management delay: work-up and treatment initiation
Time is needed to set up treatment once the patient has been
admitted in a specialized center. Waiting time should be as short
as possible so as not to delay treatment initiation, and comprises
two periods: the time needed for assessment and discussion of
the patient’s ﬁle in MDTM,  and the time needed to set up treat-
ment (surgery, radiation therapy and/or chemotherapy). Delay in
assessment or treatment results in advanced tumor and worsened
prognosis [3] (level of evidence 2), [4] (level of evidence 3). Each
week of waiting time for radiation therapy reduces tumoral con-
trol by 1% [5] (level of evidence 4). Tumor volume doubling time
ranges between 87 [6] (level of evidence 2) and 96 days [7] (level of
evidence 4), with a 10% reduction in tumoral control per month to
treatment [8] (level of evidence 4). Chen et al., in a meta-analysis of
8 studies of head and neck cancer, found a 1.15 increase in relative
risk of local recurrence after radiation therapy per month between
diagnosis and treatment initiation [9] (level of evidence 3). Huang
et al. reported a 1.17 relative risk of local recurrence for waiting
time exceeding 1 month before initiation of radiation therapy [10]
(level of evidence 3).
Schlienger, like others [11–13] (level of evidence 4), reported
more nuanced results, but still recommended a maximum 2 weeks’
waiting time for work-up [14] (level of evidence 4). Altogether, the
literature points to a negative impact of increased time to treatment
on local control and survival [3] (level of evidence 2), [4] (level of
evidence 3).
In France, the National Cancer Institute (INCa) recommends
an ideal maximum 4 weeks’ professional delay before treatment
initiation [15] (Expert opinion). These intervals are difﬁcult to
respect, due to the number of imaging examinations required for
assessment, the presence of comorbidities and the requirement
for multidisciplinary management before treatment [16] (level of
evidence 4).
Guideline 1
The objective is to facilitate the ﬁrst consultation in the
treatment center (Expert opinion).
Guideline 2
Work-up should be organized as quickly as possible so as
to initiate treatment as soon as possible.
The delay between the ﬁrst consultation with the treatment
team and collection of the data needed for decision making,
including MDTM and treatment organization, should be kept
short: ideally 2 weeks and not more than 4 weeks (Grade B).
4. Organization of ﬁrst consultation
Clinical head and neck examination is the ﬁrst step in tumor
assessment [17] (level of evidence 4). This ﬁrst contact provides
information, explaining the various necessary endoscopic exami-
nations, imaging and biologic analyses. The patient is informed of
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hould follow the guidelines of the French ENT Society (SFORL) on
re-treatment assessment in head and neck cancer. To avoid repeat
xaminations and delay, complementary examinations should
ollow the good practice criteria of the French-Language Society
f Head and Head Imaging (Société Francophone d’Imagerie Tête et
ou) [18] (Expert opinion).
Work-up scheduling should take account of the individual cen-
er’s organization so as to optimize examination [19] (Expert
pinion).
.1. Treatment anticipation
The ﬁrst consultation should enable early initiation of support-
ve care [17] (Expert opinion), with an onco-geriatrician’s opinion
f required by the patient’s age and general health status. General
ealth status is assessed by the Karnofsky index and WHO  Perfor-
ance Status, present weight and healthy weight, weight loss and
ercentage weight loss with respect to healthy weight, and BMI.
ngesta are recorded [20] (level of evidence 4). Pain is assessed on
 visual analog or numerical scale. Dental consultation is proposed,
or dental assessment and panoramic dental X-ray if radiation
herapy or chemotherapy is envisaged [17] (level of evidence 4).
his initial exchange determines head and neck cancer risk factors
smoking, alcohol abuse, cannabis), with possible withdrawal sup-
orted by specialist consultations in nicotine and alcohol addiction.
nalysis of occupational status, looking for occupational exposures,
ay  lead to referral to an occupational physician for work-station
daptation. Social environment should also be assessed, to improve
ompliance and post-treatment quality of life. There are scores that
elp detect patients with social problems (EPICES). The consulta-
ion allows psychological assessment and quantiﬁcation (Hospital
nxiety and Depression Scale [HADS] or MINI [psychiatric scale])
21] (level of evidence 1) and possible dedicated consultation. The
eed for early referral to a social worker should be assessed.
Guideline 3
The ﬁrst specialist consultation enables scheduling of the
diagnostic work-up (biopsy and extension assessment) and to
plan for the various data required for management: dental,
nutritional, psychological and social status, etc. (Grade B).
.2. Organizational aspects
Action 2.22 of the Cancer Plan consists in “providing ﬁrst-line
ealth-care workers with good practice tools for organizing the
ay-care pathway” [17] (Expert opinion).
Day surgery should be developed, mainly for economic reasons.
he priority remains, however, to do all possible to achieve rapid
iagnosis and treatment, including extension assessment (notably
maging), endoscopy with biopsies, and general assessment (car-
iac, nutritional, comorbidity) as part of the pre-treatment work-up
before surgery or radiation/chemotherapy). Assessment may  be
erformed on a day-care basis or under conventional admission
ccording to patient-related criteria, place of residence (distance
rom reference center) and the time needed for the work-up.
Guideline 4
Initial work-up may  be performed on a day-care basis orunder conventional admission according to technical possibil-
ities, type of patient and respect of recommended treatment
waiting times (Expert opinion).y, Head and Neck diseases 132 (2015) 205–208 207
5. Supportive care
Supportive care should be envisaged and planned from the start.
It is an integral part of Cancer Plan II (2009–2013) and is deﬁned as
“all care and support necessary for patients throughout their illness,
conjointly with speciﬁc treatment” [1] (Expert opinion). The main
lines comprise nutritional treatment, pain management, addiction
cessation, psychological care, social support and the development
of therapeutic education programs. Integrating supportive care
early on in management of head and neck lesions enables treat-
ment initiation to be optimized without delay. It also enhances the
patient’s tolerance of treatment.
Nutritional management should involve specialists (nutri-
tionists, dieticians) and be implemented as soon as can-
cer is suspected. Denutrition worsens postoperative morbidity
and mortality, increases infection risk and reduces treatment
efﬁcacy.
Early pain management and anticipation of pain is primor-
dial. Fifty percent of patients experience pain before treatment,
80% during treatment and 70% after treatment [22] (level of evi-
dence 4). Pain management may  be medical or use complementary
techniques such as physiotherapy, auriculotherapy, acupuncture,
homeopathy, etc.
In head and neck oncology, continuing intoxication by, for exam-
ple, nicotine or alcohol, increases the risk of recurrence or onset
of second cancer [23] (level of evidence 2). A survey performed 2
years after diagnosis of cancer found that 18% of head and neck
cancer victims continued to smoke and 25% consumed alcohol
4 times a week [24] (Expert opinion). Early and rapid manage-
ment of addiction is therefore essential [25] (level of evidence 4).
This may  consist in systematic anti-smoking consultation. Nicotine
replacement may  be prescribed, depending of the patient’s degree
of dependence [26] (level of evidence 1). Alcoholism assessment
may be suggested for patients who consume alcohol 4 or more
times a week. Other addictions involved in head and neck cancer
should also be taken into account. Referral to a psychologist or psy-
chiatrist may  be considered, according to the situation [27] (Expert
opinion).
In head and neck cancer patients, the prevalence of depressive
symptoms is between 6% and 15% [28] (Expert opinion) and the
risk of suicide is elevated (3.7-fold in women) [29] (level of evi-
dence 2). Support or medical treatment should be offered when the
diagnosis is communicated, to provide accompaniment during the
illness.
An optimal care pathway also includes adapted social manage-
ment. Support for head and neck cancer patients is essential, as
many are socially disadvantaged [30] (Expert opinion). Screening
for personal, familial or occupational difﬁculties (EPICES score)
enables the patient and family to be referred to social ser-
vices [27,28] (Expert opinion). This aspect also allows links
to be made between hospital and community physicians [31]
(Expert opinion). Externally, the social worker optimizes net-
working (home hospitalization, home nursing care, community
nurses, personal services, etc.) and the setting up of assis-
tance (social and family intervention technician, social life
auxiliary, etc) and ﬁnancial help (local personalized autonomy
allowance [Allocation Départementale Personnalisée d’Autonomie],
national health and social action for palliative care fund
[Fonds National d’Action Sanitaire et Sociale de Soins Palliatifs],
etc.).
Finally, therapeutic education improves autonomy in the
patient’s management of disease and treatment and enhances
quality of life [32] (Expert opinion). Some teams have launched
therapeutic education programs, but none have yet been validated
by the French Health Authority, although they promote hospital-
community links and improve management.
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Guideline 5
The patient’s medico-social context should systematically
be taken into account, with the help of social services whenever
required (Expert opinion).
Pain detection and management should be early (Grade A).


































[Community-hospital collaboration should be promoted for
supportive care (Expert opinion).
. Conclusion
Management of head and neck cancer in specialist centers
hould be early. It should optimize diagnostic work-up and shorten
aiting times between diagnosis and treatment initiation.
Organizing the care pathway as of the ﬁrst consultation
romises improved survival and quality of life. The hospital-
ommunity network is essential, to promote home management
nd reduce fatigue in patients and family.
Early management of head and neck cancer thus requires a
ultidisciplinary approach, and should be provided by approved
enters.
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